Cargando…

The EuroMedicines Project

The EuroMedicines Project created a single drug directory at a single time point (late 1998) to cover most of the member states of the European Union (EU) and some of the candidate states, so as to aid drug regulators, physicians and patients. It shows the wide variations in availability of medicine...

Descripción completa

Detalles Bibliográficos
Autor principal: Walley, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag Italia 2003
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3611691/
http://dx.doi.org/10.1007/s101940300011
_version_ 1782264563275661312
author Walley, Tom
author_facet Walley, Tom
author_sort Walley, Tom
collection PubMed
description The EuroMedicines Project created a single drug directory at a single time point (late 1998) to cover most of the member states of the European Union (EU) and some of the candidate states, so as to aid drug regulators, physicians and patients. It shows the wide variations in availability of medicines across Europe, e.g. there were 1974 active drugs with 18 554 branded products in Germany, compared to 1041 active drugs and 1954 products in Sweden. Only 7% of all active ingredients were available in all EU members. Among antimigraine drugs, triptans were widely available, but there were differences in licensed doses and in the ranges of products in different countries. These differences seem to have little scientific basis and to arise from different historical, cultural and commercial influences in each market. EuroMedicines Project will be a useful resource for exploring these issues.
format Online
Article
Text
id pubmed-3611691
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher Springer-Verlag Italia
record_format MEDLINE/PubMed
spelling pubmed-36116912013-04-01 The EuroMedicines Project Walley, Tom J Headache Pain Pharmacoeconomy The EuroMedicines Project created a single drug directory at a single time point (late 1998) to cover most of the member states of the European Union (EU) and some of the candidate states, so as to aid drug regulators, physicians and patients. It shows the wide variations in availability of medicines across Europe, e.g. there were 1974 active drugs with 18 554 branded products in Germany, compared to 1041 active drugs and 1954 products in Sweden. Only 7% of all active ingredients were available in all EU members. Among antimigraine drugs, triptans were widely available, but there were differences in licensed doses and in the ranges of products in different countries. These differences seem to have little scientific basis and to arise from different historical, cultural and commercial influences in each market. EuroMedicines Project will be a useful resource for exploring these issues. Springer-Verlag Italia 2003-03 /pmc/articles/PMC3611691/ http://dx.doi.org/10.1007/s101940300011 Text en © Springer-Verlag Italia 2003
spellingShingle Pharmacoeconomy
Walley, Tom
The EuroMedicines Project
title The EuroMedicines Project
title_full The EuroMedicines Project
title_fullStr The EuroMedicines Project
title_full_unstemmed The EuroMedicines Project
title_short The EuroMedicines Project
title_sort euromedicines project
topic Pharmacoeconomy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3611691/
http://dx.doi.org/10.1007/s101940300011
work_keys_str_mv AT walleytom theeuromedicinesproject
AT walleytom euromedicinesproject